We found that high TRIM21 expression predicted significant impact on clinical characteristics like lymph node metastasis (RR = 1.12; 95% CI: 0.97–1.30; P < .001; Fig. 5), tumor stage (RR = 1.06; 95% CI: 0.82–1.37; P < .001, random effects model; Supplementary Fig. 4, http://links.lww.com/MD/J129) and grade (RR = 1.07; 95% CI: 0.56–2.05; P < .001, random effects model; Supplementary Fig. 5, http://links.lww.com/MD/J130). Here, TRIM21 is linked to neoplasm.